Demand-supply imbalances, weakness in transportation fuel cracks impacted O2C segment: Mukesh Ambani
Mukesh Ambani-led Reliance posting a 2% YoY rise in profit saw its oil-to-chemicals segment results were impacted due to significant weakness in transportation fuel cracks, the company said."Significant demand-supply imbalances in downstream chemicals markets have led to multi-year low margins," said Mukesh Ambani.
"The Oil to Chemicals business posted a resilient performance despite considerable volatility in energy markets. Significant demand-supply imbalances in downstream chemicals markets have led to multi-year low margins. Our business teams ensured optimization of integrated operations and feedstock costs to enhance margin capture across value chains. The Oil & Gas business recorded its highest ever annual EBITDA led by higher production from our KGD6 and CBM blocks," said Mukesh Ambani. Oil and Gas segment revenue decreased by 0.4% due to lower gas production and lower oil offtake from KGD6, partly offset with higher gas price realisation in KGD6 Field and higher CBM production.
Reliance Industries Ltd on Friday reported a 2.4 per cent rise in its March quarter net profit, as its retail business rebounded and oil business defied global downtrend. Consolidated net profit of Rs 19,407 crore, or Rs 14.34 per share, in January-March - the fourth quarter of April 2024 to March 2025 fiscal (FY25) - was compared to Rs 18,951 crore, or Rs 14 a share, in the same period a year back, according to a stock exchange filing by the company.
Profit was also up sequentially from Rs 18,540 crore in the October-December quarter.The company's revenue from operations rose to Rs 2.6 lakh crore from Rs 2.4 lakh crore recorded in January-March 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
6 minutes ago
- Economic Times
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally," AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
&w=3840&q=100)
Business Standard
7 minutes ago
- Business Standard
Mont Vert signs $500 mn deal to build medical university in Kazakhstan
Pune-based realty group Mont Vert Group has signed a USD 500 million (around Rs 4,300 crore) contract with Kazakhstan's Big B Corp for developing a medical university and a hospital, according to a statement. Mont Vert Group will be responsible for the construction and development activities related to the project, UK-based SRAM & MRAM Group said in the statement. UK-based SRAM & MRAM Group in partnership with Big B Corporation and KAZIND Medical Group of Kazakhstan is developing a private healthcare facility in Kazakhstan. The agreement was made possible through the efforts of Big B Corporation Director Ajay Bhandari and SRAM & MRAM Group Director Mahendra Joshi, the statement said. The group in October last year announced getting approval from the Kazakh government for 243 hectares of land at Astana and 100 hectares at Almaty for Medical University, a multi-specialty Hospital and a 5-star hotel. The medical college will teach 10,000 students and have a multi-specialty hospital with 1,000 beds. "Mont Vert Group represents the highest standards of Indian real estate leadership," said Sailesh Lachu Hiranandani, Chairman, SRAM & MRAM Group. SRAM & MRAM Group, a global conglomerate with interests across fintech, healthcare, AI, agriculture, biotechnology, and more, recently completed 30 years of operations. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard
21 minutes ago
- Business Standard
Oswal Pumps IPO subscribed 42%
The offer received bids for 67.83 lakh shares as against 1.61 crore shares on offer. The initial public offer of Oswal Pumps received bids for 67,83,552 shares as against 1,62,12,980 shares on offer, according to stock exchange data at 17:00 IST on Friday (13 June 2025). The issue was subscribed 0.42 times. The issue opened for bidding on 13 June 2025 and it will close on 17 June 2025. The price band of the IPO is fixed between Rs 584 614 per share. An investor can bid for a minimum of 24 equity shares and in multiples thereof. The issue comprises both a fresh issue of equity shares upto Rs 890 crore and an offer for sale up to 81,00,000 equity shares by Vivek Gupta, one of the prompters of the company. The company proposes to utilize the net proceeds from the issue towards capital expenditure of Rs 89.86 crore; Rs 272.76 crore for investment in its wholly-owned subsidiary, Oswal Solar, in the form of equity, for funding the setting up of new manufacturing units at Karnal, Haryana; Rs 280 crore for pre-payment/ re-payment, in part or full, of certain outstanding borrowings availed by the company; Rs 31.00 crore for investment in its wholly-owned Subsidiary, Oswal Solar, in the form of equity, for repayment/prepayment, in part or full, of certain outstanding borrowings availed by Oswal Solar; and general corporate purposes. Oswal Pumps, established by Padam Sain Gupta (father of Vivek Gupta, one of its promoters and chairman and managing director), has commenced its operations in 2003 with the manufacturing of low-speed monoblock pumps. The company manufactures solar-powered and grid-connected submersible and monoblock pumps, electric motors comprising induction and submersible motors as well as solar modules, which it sells under the Oswal brand. It is one of the few fully integrated Turnkey Solar Pumping Systems providers in India with the capability to manufacture solar powered agricultural pumps, solar modules and pump controllers and provide installation services for such systems. Sales of majority of its products are geographically concentrated, with the four states of Haryana, Maharashtra, UttarPradesh and Rajasthan accounting for 90.47% and 90.78% of its 9mFY25 and FY24 revenue Ahead of the IPO, Oswal Pumps on Thursday, 12 June 2025, raised Rs 416.20 crore from anchor investors. The board allotted 67,78,533 shares at Rs 614 each to 25 anchor investors. The firm reported a consolidated net profit of Rs 215.80 crore and total income of Rs 1,065.67 crore for the nine months ended on 31 December 2024.
